Restrictions concerning the therapeutic benefits of CCL2/CCR2 antagonists and antibodies in the management of cardiovascular disorders encompass the assessment of off-target consequences, toxicity [21,42], and the possibility of compensatory activity by alternative receptors. The gene discussed is CCR2; the disease is cardiovascular disorder.